Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642642 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring
A Phase 2 study, sponsored by Castle Creek Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT00642642 is a Phase 2 study that has completed, run by Castle Creek Biosciences. The registered enrollment target is 122 participants.
The verdict
NCT00642642, a Phase 2 study, has completed, sponsored by Castle Creek Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM and placebo when administered to facial acne scars.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Autologous Human Fibroblasts (azficel-T)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642642
The ClinicalTrials.gov registry entry for NCT00642642 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Castle Creek Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00642642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642642 about?
NCT00642642 is a clinical study titled "Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring". The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM and placebo when administered to facial acne scars.
What is the current status of trial NCT00642642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2007-11. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00642642?
The interventions under investigation include: Placebo (BIOLOGICAL), Autologous Human Fibroblasts (azficel-T) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00642642?
This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.